Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 440Rectal Neoplasms 209Colonic Neoplasms 202Pancreatic Neoplasms 131Stomach Neoplasms 117Neoplasm Metastasis 97Neoplasms 64Esophageal Neoplasms 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Lymphoma 49Leukemia 41Carcinoma, Hepatocellular 41Adenocarcinoma Of Esophagus 37Burkitt Lymphoma 33Adenocarcinoma 29Cholangiocarcinoma 26Biliary Tract Neoplasms 23Carcinoma, Non-Small-Cell Lung 21Gastrointestinal Neoplasms 20Gallbladder Neoplasms 20Lymphoma, Non-Hodgkin 19Esophageal Squamous Cell Carcinoma 15Osteosarcoma 14Liver Neoplasms 14Bile Duct Neoplasms 14Unspecified Adult Solid Tumor, Protocol Specific 13Lymphoma, Large B-Cell, Diffuse 13Leukemia, Biphenotypic, Acute 13Ovarian Neoplasms 12Leukemia, Myeloid, Acute 12

Interventions

Leucovorin 2Irinotecan 2Fluorouracil 2Cetuximab 2spartalizumab 1pembrolizumab 1camrelizumab 1Radiosurgery 1Oxaliplatin 1Oncolytic Virotherapy 1KD025 1IFL protocol 1HLX07 1Folfox protocol 1Drug Therapy 1CCT239065 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
CRC × Leucovorin × Clear all
NCT07381309 2026-04-28

VVSHIP

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Not yet recruiting
114 enrolled
Gastrointestinal

CRC

NCT07204574 2025-10-02

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Chang Gung Memorial Hospital

Phase 1/2 Recruiting
40 enrolled

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡